BioSpace News Archive

Cook Medical announced it signed a letter of intent with CooperCompanies to sell the entirety of Cook’s Reproductive Health business within the MedSurg division.

Astellas Pharma Inc. today announced positive interim safety data from FORTIS, the Phase I/II clinical trial evaluating AT845.

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the enrollment and dosing of more than 100 subjects in the Company’s ongoing Phase 2/3 study of Tempol for the treatment of COVID-19.

Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough-to-treat cancers, is proud to present Dr. Volker W. Stieber, MD, as a welcome addition to its distinguished Neuro-Oncology Advisory Board.

RedHill Biopharma Ltd. (NASDAQ: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced results from two recently completed prespecified analyses from the oral opaganib (ABC294640)[1] Phase 2/3 study in hospitalized severe COVID-19.

According to Emergen Research, the global cerebrospinal fluid management market size was USD 1.50 billion in 2020 and is expected to reach USD 2.09 billion in 2028 and register a revenue CAGR of 4.5% during the forecast period, 2021-2028.

According to Emergen Research, the global brachytherapy market size was USD 396.4 million in 2019 and is expected to reach USD 548.8 million in 2027 and register a revenue CAGR of 4.1% during the forecast period.

The industry analysis report is considered a valuable source of information about the global Intra Oral Scanners for Digital Impression industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

The National Marrow Donor Program® /Be The Match®, a global leader in cellular therapy, awarded this year’s Amy Strelzer Manasevit Research Program grant to Dan Peltier, MD, PhD.

AB Science SA announced that Professor Olivier Hermine, President of the Scientific Committee of AB Science, will deliver a presentation on the amyotrophic lateral sclerosis masitinib development program to an audience of key opinion leaders and decision-makers in the field of ALS research and healthcare policy, at the up-coming ALS Drug Development Summit in Boston, USA.